Open AccessInteraction between Zinc, GPR39, BDNF and Neuropeptides in Depression
Author(s) -
Katarzyna Młyniec
Publication year - 2021
Publication title -
current neuropharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.955
H-Index - 73
eISSN - 1875-6190
pISSN - 1570-159X
DOI - 10.2174/1570159x19666210225153404
Subject(s) - depression (economics) , neuropeptide , neuroscience , zinc , medicine , biology , chemistry , receptor , organic chemistry , economics , macroeconomics
As one of the most important elements in our body, zinc plays a part in both the pathophysiologyof depression and the antidepressant response. Patients suffering from major depression showsignificantly reduced zinc levels, which are normalized following successful antidepressant treatment.Recent studies have shown the interaction between zinc, GPR39 and neuropeptides, including galaninand neuropeptide Y (NPY). The zinc-sensing receptor GPR39 forms heterotrimers with 5-HT 1A andthe galanin receptor GalR 1 upon their co-expression in mammalian cells. The oligomerization of theseheterotrimers is regulated by the zinc concentration, and this may have an influence on depressive-likebehavior. The antidepressant-like effect of zinc is linked to elevated levels of brain-derived neurotrophicfactor (BDNF) in brain structures associated with emotion, such as the hippocampus and theamygdala. BDNF regulates neuropeptides, including NPY, cholecystokinin (CCK), and substance P orgalanin, which are also implicated in mood disorders. This review focuses for the first time on the interactionbetween zinc, the GPR39 zinc receptor, BDNF and selected neuropeptides in terms of depressionin order to determine its possible role in the neuropharmacology of that illness.